Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: A retrospective analysis covering a 34-year period

Helen H.W Chen, Lily Fong, Ih Jen Su, Lai Lei Ting, Ruey Long Hong, Henry W.C. Leung, Louis Tak Lui

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Lethal midline granuloma (LMG) is characterized by progressive ulceration and destruction of the midfacial tissue. It occurs more frequently in Oriental than in Western populations. Because of the progress in clinical pathology and immunohistochemistry, most cases have been proven to be malignant lymphomas, especially of T-cell lineage. We describe 92 cases of lethal midline granuloma or centrofacial malignant lymphoma in the period 1959-1993. All received complete courses of radiotherapy. Twenty of them also received combination chemotherapy. Thirty-six cases had specimens available for immunohistochemical study; 25 (69%) of these had a T-cell phenotype, and 6 (17%) were of B-cell lineage. The dose to the nasal region was in the range of 3000-7500 cGy in 11-58 days, and to the neck 3000-6400 cGy in 11-48 days. The overall survival rate for the LMGs was 59.5% at 5 years and 56.2% at 10 years (Kaplan-Meier). Combined chemotherapy seemed not to improve the overall survival in this study (p = 0.63), but the patient number was too small to make a firm conclusion. Based on the results of this study, we recommend a dose of 4500-5000 cGy to the midfacial region, since a higher dosage did not improve the treatment results (p = 0.88). Irradiation has a definite role in good locoregional control of this disease. The recent clarification of the disease nature and the recognition of the background clinicopathological features should provide valuable information for future patient management and prospective studies.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalRadiotherapy and Oncology
Volume38
Issue number1
DOIs
Publication statusPublished - 1996 Jan 1

Fingerprint

Lethal Midline Granuloma
T-Cell Lymphoma
Cell Lineage
Lymphoma
Radiotherapy
T-Lymphocytes
Clinical Pathology
Combination Drug Therapy
Nose
B-Lymphocytes
Neck
Survival Rate
Immunohistochemistry
Prospective Studies
Phenotype
Drug Therapy
Survival
Population
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Chen, Helen H.W ; Fong, Lily ; Su, Ih Jen ; Ting, Lai Lei ; Hong, Ruey Long ; Leung, Henry W.C. ; Lui, Louis Tak. / Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma : A retrospective analysis covering a 34-year period. In: Radiotherapy and Oncology. 1996 ; Vol. 38, No. 1. pp. 1-6.
@article{3440ddadf75f4ba6b2bd26e6de434077,
title = "Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: A retrospective analysis covering a 34-year period",
abstract = "Lethal midline granuloma (LMG) is characterized by progressive ulceration and destruction of the midfacial tissue. It occurs more frequently in Oriental than in Western populations. Because of the progress in clinical pathology and immunohistochemistry, most cases have been proven to be malignant lymphomas, especially of T-cell lineage. We describe 92 cases of lethal midline granuloma or centrofacial malignant lymphoma in the period 1959-1993. All received complete courses of radiotherapy. Twenty of them also received combination chemotherapy. Thirty-six cases had specimens available for immunohistochemical study; 25 (69{\%}) of these had a T-cell phenotype, and 6 (17{\%}) were of B-cell lineage. The dose to the nasal region was in the range of 3000-7500 cGy in 11-58 days, and to the neck 3000-6400 cGy in 11-48 days. The overall survival rate for the LMGs was 59.5{\%} at 5 years and 56.2{\%} at 10 years (Kaplan-Meier). Combined chemotherapy seemed not to improve the overall survival in this study (p = 0.63), but the patient number was too small to make a firm conclusion. Based on the results of this study, we recommend a dose of 4500-5000 cGy to the midfacial region, since a higher dosage did not improve the treatment results (p = 0.88). Irradiation has a definite role in good locoregional control of this disease. The recent clarification of the disease nature and the recognition of the background clinicopathological features should provide valuable information for future patient management and prospective studies.",
author = "Chen, {Helen H.W} and Lily Fong and Su, {Ih Jen} and Ting, {Lai Lei} and Hong, {Ruey Long} and Leung, {Henry W.C.} and Lui, {Louis Tak}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0167-8140(95)01668-6",
language = "English",
volume = "38",
pages = "1--6",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma : A retrospective analysis covering a 34-year period. / Chen, Helen H.W; Fong, Lily; Su, Ih Jen; Ting, Lai Lei; Hong, Ruey Long; Leung, Henry W.C.; Lui, Louis Tak.

In: Radiotherapy and Oncology, Vol. 38, No. 1, 01.01.1996, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma

T2 - A retrospective analysis covering a 34-year period

AU - Chen, Helen H.W

AU - Fong, Lily

AU - Su, Ih Jen

AU - Ting, Lai Lei

AU - Hong, Ruey Long

AU - Leung, Henry W.C.

AU - Lui, Louis Tak

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Lethal midline granuloma (LMG) is characterized by progressive ulceration and destruction of the midfacial tissue. It occurs more frequently in Oriental than in Western populations. Because of the progress in clinical pathology and immunohistochemistry, most cases have been proven to be malignant lymphomas, especially of T-cell lineage. We describe 92 cases of lethal midline granuloma or centrofacial malignant lymphoma in the period 1959-1993. All received complete courses of radiotherapy. Twenty of them also received combination chemotherapy. Thirty-six cases had specimens available for immunohistochemical study; 25 (69%) of these had a T-cell phenotype, and 6 (17%) were of B-cell lineage. The dose to the nasal region was in the range of 3000-7500 cGy in 11-58 days, and to the neck 3000-6400 cGy in 11-48 days. The overall survival rate for the LMGs was 59.5% at 5 years and 56.2% at 10 years (Kaplan-Meier). Combined chemotherapy seemed not to improve the overall survival in this study (p = 0.63), but the patient number was too small to make a firm conclusion. Based on the results of this study, we recommend a dose of 4500-5000 cGy to the midfacial region, since a higher dosage did not improve the treatment results (p = 0.88). Irradiation has a definite role in good locoregional control of this disease. The recent clarification of the disease nature and the recognition of the background clinicopathological features should provide valuable information for future patient management and prospective studies.

AB - Lethal midline granuloma (LMG) is characterized by progressive ulceration and destruction of the midfacial tissue. It occurs more frequently in Oriental than in Western populations. Because of the progress in clinical pathology and immunohistochemistry, most cases have been proven to be malignant lymphomas, especially of T-cell lineage. We describe 92 cases of lethal midline granuloma or centrofacial malignant lymphoma in the period 1959-1993. All received complete courses of radiotherapy. Twenty of them also received combination chemotherapy. Thirty-six cases had specimens available for immunohistochemical study; 25 (69%) of these had a T-cell phenotype, and 6 (17%) were of B-cell lineage. The dose to the nasal region was in the range of 3000-7500 cGy in 11-58 days, and to the neck 3000-6400 cGy in 11-48 days. The overall survival rate for the LMGs was 59.5% at 5 years and 56.2% at 10 years (Kaplan-Meier). Combined chemotherapy seemed not to improve the overall survival in this study (p = 0.63), but the patient number was too small to make a firm conclusion. Based on the results of this study, we recommend a dose of 4500-5000 cGy to the midfacial region, since a higher dosage did not improve the treatment results (p = 0.88). Irradiation has a definite role in good locoregional control of this disease. The recent clarification of the disease nature and the recognition of the background clinicopathological features should provide valuable information for future patient management and prospective studies.

UR - http://www.scopus.com/inward/record.url?scp=0030061372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030061372&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(95)01668-6

DO - 10.1016/0167-8140(95)01668-6

M3 - Article

C2 - 8850419

AN - SCOPUS:0030061372

VL - 38

SP - 1

EP - 6

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -